MyFinsight
Home
Blog
About
Contact
Download
Download image
Issuance of common stock
under the offering...
$93,540K
Issuance of common stock
under the offering...
$9,683K
Issuance of common stock
under stock purchase...
$7,500K
Issuance of common stock -
2020 espp
$1,253K
Issuance of common stock
upon exercise of...
$984K
Net cash provided by
financing activities
$112,960K
Net decrease in cash
and cash...
-$89,095K
Canceled cashflow
$112,960K
Stock-based compensation
expense
$22,016K
Accrued and other
liabilities
$8,152K
Accounts payable
$6,773K
Depreciation and
amortization
$4,694K
Amortization of right-of-use
assets
$2,931K
Maturities of marketable
securities
$350,384K
Net cash used in
operating activities
-$109,082K
Canceled cashflow
$44,566K
Net cash used in
investing activities
-$92,973K
Canceled cashflow
$350,384K
Net loss
-$140,109K
Other assets
$4,927K
Net accretion of
discount on marketable...
$4,734K
Operating lease
liabilities
-$3,193K
Prepaid expenses and
other current assets
$424K
Deferred revenue
-$209K
Change in fair value of
derivative liability
-$52K
Purchase of marketable
securities
$442,821K
Acquisition of property and
equipment
$536K
Back
Back
Cash Flow
source: myfinsight.com
4D Molecular Therapeutics, Inc. (FDMT)
4D Molecular Therapeutics, Inc. (FDMT)